Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome

Luciana dos Santos Henriques, Fabíola de Marcos Matos, Maria Helena Vaisbich, Luciana dos Santos Henriques, Fabíola de Marcos Matos, Maria Helena Vaisbich

Abstract

Objective: We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin. To compare the pharmacokinetic parameters of cyclosporin in idiopathic nephrotic syndrome during remission and relapse of the nephrotic state.

Method: The pharmacokinetic profile of cyclosporin was evaluated with the 12-hour area under the time-concentration curve (auc0-12) using seven time-point samples. This procedure was performed on each patient during remission and relapse with the same cyclosporin dose in mg/kg/day. The 12-hour area under the time-concentration curve was calculated using the trapezoidal rule. All of the pharmacokinetic parameters and the resumed 4-hour area under the time-concentration curve were correlated with the 12-hour area under the time-concentration curve. ClinicalTrials.gov: NCT01616446.

Results: There were no significant differences in any parameters of the pharmacokinetic of cyclosporin during remission and relapse, even when the data were normalized by dose. The best correlation with the 12-hour area under the time-concentration curve was the 4-hour area under the time-concentration curve on remission and relapse of the disease, followed by the 2-hour level after cyclosporin (c2) dosing in both disease states.

Conclusions: These data indicate that the same parameters used for cyclosporin therapeutic monitoring estimated during the nephrotic state can also be used during remission. Larger controlled studies are needed to confirm these findings.

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1
Figure 1
AUC0-12 during remission and relapse of INS.

References

    1. International Study of Kidney Disease in Childreen. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr. 1981;98(4):561–4.
    1. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007;72(12):1429–47.
    1. Manrique-Rodríguez S, Fernandez-Llamazares C, Sanjurjo-Saez M. Pharmacotherapeutic review and uptade of idiopathic nephrotic syndrome in children. Pharm World Sci. 2010;32(3):314–21.
    1. Del Rio M, Kaskel F. Evaluation and management of steroid-unresponsive nephrotic syndrome. Curr Opin Pediatr. 2008;20(2):151–6.
    1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–39.
    1. Sümegi V, Haszon I, Bereczki C, Papp F, Túri S. Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2008;23(7):1085–92.
    1. Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G. Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol. 2005;20(1):25–9.
    1. El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant. 2005;20(11):2433–8.
    1. Briggs WA, Gao ZH, Xing JJ, Scheel PJ, Gimenez LF, Samaniego MD, et al. Suppression of dialysis patients' lymphocyte IL-2R expression by glucocorticoids and cyclosporine. Cytokine. 1997;9(8):624–8.
    1. Resch K, Szamel M. Molecular mechanisms of the immunosuppressive action of cyclosporin A. Int J Immunopharmacol. 1997;19(9–10):579–85.
    1. Desassis JF, Raats CJ, Bakker MA, van den Born J, Berden JH. Antiproteinuric effect of ciclosporin A in adriamycin nephropathy in rats. Nephron. 1997;75(3):336–41.
    1. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–8.
    1. Medeiros M, Pérez-Urizar J, Pedraza-Chaverri J, Muñoz-Arizpe R, Castañeda-Hernández G. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. Can J Physiol Pharmacol. 2007;85(5):502–6.
    1. Weber LT, Armstrong VW, Shipkova M, Feneberg R, Wiesel M, Mehls O, et al. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit. 2004;26(4):415–24.
    1. Britto ZM, David-Neto E, Lemos FC, Pereira LM, Castro MC, Fonseca JÁ, et al. Identifying cyclosporine blood levels associated with the prevention of renal transplant rejection: a single-center, randomized prospective study. Transplant Proc. 2004;36(9):2649–55.
    1. Medeiros M, Pérez-Urizar J, Mejía-Gaviria N, Ramírez-López E, Castañeda-Hernández G, Muñoz R. Decreased cyclosporine exposure during the remission of nephrotic syndrome. Pediatr Nephrol. 2007;22(1):84–90.
    1. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. Pediatr Clin North Am. 1987;34(3):571–90.
    1. Abbott Laboratories. TDxFLx cyclosporine monoclonal whole blood. Package insert 9797-60 E 34-0060/R7 2001:1-6 Abbott Laboratories Abbott Park, IL.
    1. Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med. 2008;47(18):1567–72.
    1. Faulds D, Goa KL, Benfield P. Cyclosporin – a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45(6):953–1040.
    1. Nozu K, Iijima K, Sakaeda T, Okumura K, Nakanishi K, Yoshikawa N, et al. Cyclosporin A absorption profiles in children with nephrotic syndrome. Pediatr Nephrol. 2005;20(7):910–3.
    1. Dello Strologo L, Campagnano P, Federici G, Rizzoni G. Cyclosporine A monitoring in children: abbreviated area under curve formulas and C2 level. Pediatr Nephrol. 1999;13(2):95–7.
    1. Von Ahsen N, Helmhold M, Schütz E, Eisenhauer T, Armstrong VW, Oellerich M. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. Ther Drug Monit. 1997;19(2):140–5.
    1. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter Trial. Kidney Int. 2008;73(10):1167–73.
    1. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporin microemulsion therapy in immediate posttransplant period. Clin Chem. 1996;42:1294–6.
    1. Kalyoncu M, Topaloglu R, Bayrakci U, Bakkaloglu A, Besbas N, Ozaltin F, et al. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. Pediatr Transplant. 2006;10(2):168–71.
    1. Kyllönen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Transplantation. 2006;81(7):1010–5.
    1. Strong DK, Lai A, Primmett D, White CT, Lirenman DS, Carter JE, et al. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients. Pediatr Transplant. 2005;9(5):566–73.
    1. Critterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Trasnplant Proc. 2004;36:420–5.
    1. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002;73(9Suppl):S3–11.
    1. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68(9):1356–61.
    1. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant. 2001;1(4):325–33.
    1. Van Rossum HH, Fijter JW, Van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit. 2010;32:3–10.
    1. Marquet P. Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary. Clin Chem. 2010;56(5):736–9.
    1. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011;12(9):1293–303.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться